📊 Analyst Consensus & Targets
- Analyst Rating: Buy
- Price Target: $95.80071
- Sector: Healthcare – Medical Devices
💡 The Growth Thesis
Buy Consensus: Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. Analysts project a 12.4% potential upside. Currently trading at a Forward P/E of 29.688108.